Results 111 to 120 of about 43,753 (252)
Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura +3 more
wiley +1 more source
PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer. [PDF]
Ghosh M +7 more
europepmc +1 more source
Multi‐region sequencing of 57 BRCA1‐associated breast cancers identified TP53 as the dominant initial driver, defining a triple‐negative subgroup with biallelic BRCA1 loss and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers and linked to reduced HRD, EMT activation, and a trend toward worse survival.
Li Hu +13 more
wiley +1 more source
Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials. [PDF]
Chao Z +11 more
europepmc +1 more source
AI‐based spatial analysis of tumor‐infiltrating lymphocytes in ovarian cancer revealed the highest infiltration in high‐grade serous carcinoma. Integrating pathology‐based immune phenotypes with HRD status provided additional prognostic insight and highlighted distinct relationships between TILs and genomic structure.
Kohei Hamada +17 more
wiley +1 more source
Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment. [PDF]
Zhao D, Long X, Wang J.
europepmc +1 more source
New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi +2 more
wiley +1 more source
ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis). [PDF]
Guo Y +8 more
europepmc +1 more source
Chromosomal DNA double‐strand breaks (DSBs) are repaired by homologous recombination and nonhomologous end joining (NHEJ). Recent work has additionally established theta‐mediated end‐joining (TMEJ) as a mechanism for DSB joining. Cells lacking NHEJ and TMEJ can repair DSBs in a homology‐dependent manner.
Shinta Saito +6 more
wiley +1 more source

